within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB11_Aumolertinib;

model Aumolertinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.81,
    Cl = 5.333333333333333e-06,
    adminDuration = 600,
    adminMass = 110 / 1000000,
    adminCount = 1,
    Vd = 0.306,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.012,
    Tlag = 10.799999999999999,
    Vdp = 0.391,
    k12 = 7.527777777777778e-06,
    k21 = 7.527777777777778e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Aumolertinib</td></tr><tr><td>ATC code:</td><td>L01EB11</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>110</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>306</td><td>L</td></tr>
    <tr><td>clearance:</td><td>19.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Aumolertinib is a third-generation, oral, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). It is approved in China for the treatment of patients with advanced or metastatic NSCLC harboring EGFR mutations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with advanced NSCLC following oral administration. Population PK analyses and clinical studies support the following estimates.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EB11 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Aumolertinib;
